Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.

Akshay B JainSteve KantersReena KhuranaJagoda KissockNaomi SeverinSara G Stafford

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)

This study supports switching T2DM patients on liraglutide or dulaglutide to injectable semaglutide to achieve further reductions in HbA1c and weight. Although a small number of GSEs occurred, semaglutide was well tolerated by the majority of the patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
prognostic factors
systematic review
physical activity
body mass index
cross sectional
weight gain